Targeting IMPDH2 by Casticin attenuates psoriatic inflammation by suppressing STAT3 activation in keratinocytes
International Immunopharmacology · 2026
DOI: 10.1016/j.intimp.2026.117249 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2026. Verfasst von Jia Guo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha 410008, Hunan, China; National Engineering Resea…. Hauptthemen laut MEDLINE: IMP Dehydrogenase, STAT3 Transcription Factor, Keratinocytes, Psoriasis. Die Arbeit nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Hunan Provincial Natural Science Foundation, Science and Technology Program of Hunan Province.
Abstract (Originalsprache)
Psoriasis is a chronic immune-mediated inflammatory disease. Inosine Monophosphate Dehydrogenase 2 (IMPDH2), the rate-limiting enzyme in de novo guanine nucleotide biosynthesis, is upregulated during cytokine-mediated inflammatory responses, yet its specific role in keratinocyte biology and psoriatic pathogenesis remains unexplored. Here, we identify IMPDH2 as a critical metabolic regulator of psoriatic inflammation. Integrated analysis of bulk and single-cell RNA sequencing datasets revealed consistent upregulation of IMPDH2 in psoriatic keratinocytes, which was further validated by immunofluorescence staining of patient skin biopsies. In an imiquimod (IMQ)-induced murine psoriasis model, pharmacological inhibition of IMPDH2 with Casticin attenuated disease progression and alleviated epidermal inflammation. Mechanistically, IMPDH2 promotes keratinocyte inflammation through GTP-dependent activation of STAT3 signaling: IMPDH2 knockdown or inhibition reduced STAT3 phosphorylation and suppressed inflammatory responses, effects that were reversed by exogenous GTP supplementation, whereas IMPDH2 overexpression enhanced STAT3 phosphorylation and inflammation. Supporting a direct causal link between IMPDH2 and STAT3, the STAT3 activator colivelin reversed the effect of IMPDH2 inhibition, while the STAT3 inhibitor Stattic abrogated the effect of IMPDH2 overexpression. Collectively, this study establishes a previously unrecognized IMPDH2-GTP-STAT3 axis driving keratinocyte inflammation and nominates Casticin as a promising therapeutic candidate for psoriasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha 410008, Hunan, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Chan…
- Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, Hunan, China; Provincial Clinical Research Center for Rheumatic and Immunologic Diseases, Xiangya Hospital, Changsha, Huna…
Förderung
- National Natural Science Foundation of China
- Hunan Provincial Natural Science Foundation
- Science and Technology Program of Hunan Province
- China Postdoctoral Science Foundation
Zitieren
APA
Guo, J., Hong, Q., Li, W., & Hu, X. (2026). Targeting IMPDH2 by Casticin attenuates psoriatic inflammation by suppressing STAT3 activation in keratinocytes. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2026.117249
Vancouver
Guo J, Hong Q, Li W, Hu X. Targeting IMPDH2 by Casticin attenuates psoriatic inflammation by suppressing STAT3 activation in keratinocytes. International Immunopharmacology. 2026. doi:10.1016/j.intimp.2026.117249
BibTeX
@article{Guo2026,
author = {Guo, Jia and Hong, Qingyu and Li, Weina and Hu, Xiaoru},
title = {Targeting IMPDH2 by Casticin attenuates psoriatic inflammation by suppressing STAT3 activation in keratinocytes},
journal = {International Immunopharmacology},
year = {2026},
doi = {10.1016/j.intimp.2026.117249}
}
EUVIMED